ExpreS2ion Biotechnologies is currently carrying out a rights issue with preferential rights for existing shareholders. If fully subscribed, the rights issue will raise about SEK 102m in cash before costs in the first round, with the potential for an equal amount through a warrant program. Around 50% of the right issue is covered.
In a virtual live event today with CEO Bent Frandsen, we went through details and the plan of the rights issue, among others the use of the proceeds, and the options you have as an investor with preferential rights.
For further information, the prospectus can be found here: https://investor.expres2ionbio.com/wp-content/uploads/2023/03/2023-Rights-Issue-Prospectus-ENG.pdf
HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 17:00, 31 March 2023.